1) Eckardt KU, Coresh J, Devuyst O, Johnson RJ, Köttgen
A, Levey AS, Levin A: Evolving importance of kidney
disease: from subspecialty to global health burden. Lancet,
2013; 382: 158-169
2) Levin A, Tonelli M, Bonventre J, Coresh J, Donner JA,
Fogo AB, Fox CS, Gansevoort RT, Heerspink HJL,
Jardine M, Kasiske B, Köttgen A, Kretzler M, Levey AS,
Luyckx VA, Mehta R, Moe O, Obrador G, Pannu N,
Parikh CR, Perkovic V, Pollock C, Stenvinkel P, Tuttle
KR, Wheeler DC, Eckardt KU; ISN Global Kidney
Health Summit participants: Global kidney health 2017
and beyond: a roadmap for closing gaps in care, research,
and policy. Lancet, 2017; 390: 1888-1917
3) Vidal-Petiot E, Greenlaw N, Kalra PR, Garcia-Moll X,
Tardif JC, Ford I, Zamorano J, Ferrari R, Tendera M, Fox
KM, Philippe Gabriel Steg PG; on behalf of the
CLARIFY investigators: Chronic Kidney Disease Has a
Graded Association with Death and Cardiovascular
Outcomes in Stable Coronary Artery Disease: An Analysis
of 21,911 Patients from the CLARIFY Registry. J Clin
Med, 2019; 9: 4
4) Gassett AJ, Sheppard L, McClelland RL, Olives C,
Kronmal R, Blaha MJ, Budoff M, Kaufman JD: Risk
Factors for Long Term Coronary Artery Calcium
Progression in the Multi Ethnic Study of Atherosclerosis.
J Am Heart Assoc, 2015; 4: e001726
5) Gansevoort RT, Correa-Rotter R, Hemmelgarn BR, Jafar
TH, Heerspink HJ, Mann JF, Matsushita K, Wen CP:
Chronic kidney disease and cardiovascular risk:
epidemiology, mechanisms, and prevention. Lancet, 2013;
382: 339-352
6) DeFilippis AP, Kramer HJ, Katz R, Wong ND, Bertoni
AG, Carr J, Budoff MJ, Blumenthal RS, Nasir K:
Association between coronary artery calcification
progression and microalbuminuria: the MESA study.
JACC Cardiovasc Imaging, 2010; 3: 595-604
7) Jassal SK, Chonchol M, Laughlin GA, Cummins KM,
Smits G, Kramer CK, Ix JH, Barrett-Connor E: Kidney
function and progression of coronary artery calcium in
community-dwelling older adults (from the Rancho
Bernardo Study). Am J Cardiol, 2012; 110: 1425-1433
8) Nakamura S, Ishibashi-Ueda H, Niizuma S, Yoshihara F,
Horio T, Kawano Y: Coronary calcification in patients
with chronic kidney disease and coronary artery disease.
Clin J Am Soc Nephro, 2009; 4: 1892-1900
9) Fox CS, Larson MG, Keyes MJ, Levy D, Clouse ME,
Culleton B, O’Donnell CJ: Kidney function is inversely
associated with coronary artery calcification in men and
women free of cardiovascular disease: the Framingham
Heart Study. Kidney Int, 2004; 66: 2017-2021
10) El Barzouhi A, Elias-Smale S, Dehghan A, VliegenthartProença R, Oudkerk M, Hofman A, Witteman JC: Renal
function is related to severity of coronary artery
calcification in elderly persons: the Rotterdam study. PloS
One, 2011; 6: e16738
11) Suh-Chiou C, Moysés RM, Bittencourt MS, Bensenor
IM, Lotufo PA: Chronic kidney disease and coronary
artery calcification in the Brazilian Longitudinal Study of
Adult Health (ELSA-Brasil). Clin Cardiol, 2017; 40:
1309-1315
12) Lees JS, Welsh CE, Celis-Morales CA, Mackay D, Lewsey
J, Gray SR, Lyall DM, Cleland JG, Gill JMR, Jhund PS,
Pell J, Sattar N, Welsh P, Mark PB: Glomerular filtration
rate by differing measures, albuminuria and prediction of
cardiovascular disease, mortality and end-stage kidney
disease. Nat Med, 2019; 25: 1753-1760
13) Peralta CA, Shlipak MG, Judd S, Cushman M, McClellan
W, Zakai NA, Safford MM, Zhang X, Muntner P,
Warnock D: Detection of Chronic Kidney Disease With
Creatinine, Cystatin C, and Urine Albumin-to-Creatinine
Ratio and Association With Progression to End-Stage
Renal Disease and Mortality. JAMA, 2011; 305: 15451552
14) Kadota A, Miura K, Okamura T, Fujiyoshi A, Ohkubo T,
Kadowaki T, Takashima N, Hisamatsu T, Nakamura Y,
Advance Publication Journal of Atherosclerosis and Thrombosis
Accepted for publication: September 12, 2021 Published online: October 22, 2021
Kidney Function and CAC Progression
Kasagi F, Maegawa H, Kashiwagi A, Ueshima H; SESSA
Research Group; NIPPON DATA80/90 Research Group:
Carotid intima-media thickness and plaque in apparently
healthy Japanese individuals with an estimated 10-year
absolute risk of CAD death according to the Japan
Atherosclerosis Society (JAS) guidelines 2012: the Shiga
Epidemiological Study of Subclinical Atherosclerosis
(SESSA). J Atheroscler Thromb, 2013; 20: 755-766
15) Fujiyoshi A, Miura K, Ohkubo T, Kadowaki T, Kadowaki
S, Zaid M, Hisamatsu T, Sekikawa A, Budoff MJ, Liu K,
Ueshima H; SESSA Research Group; MESA Research
Group: Cross-sectional comparison of coronary artery
calcium scores between Caucasian men in the United
States and Japanese men in Japan: the multi-ethnic study
of atherosclerosis and the Shiga epidemiological study of
subclinical atherosclerosis. Am J Epidemiol, 2014; 180:
590-598
16) Tudor-Locke C, Giles-Corti B, Knuiman M, McCormack
G: Tracking of pedometer-determined physical activity in
adults who relocate: results from RESIDE. Int J Behav
Nutr Phys Act, 2008; 5: 39
17) Friedewald WT, Levy RI, Fredrickson DS: Estimation of
the concentration of low-density lipoprotein cholesterol
in plasma, without use of the preparative ultracentrifuge.
Clin Chem, 1972; 18: 499-502
18) Kashiwagi A, Kasuga M, Araki E, Oka Y, Hanafusa T, Ito
H, Tominaga M, Oikawa S, Noda M, Kawamura T,
Sanke T, Namba M, Hashiramoto M, Sasahara T, Nishio
Y, Kuwa K, Ueki K, Takei I, Umemoto M, Murakami M,
Yamakado M, Yatomi Y, Ohashi H: International clinical
harmonization of glycated hemoglobin in Japan.
International clinical harmonization of glycated
hemoglobin in Japan: From Japan Diabetes Society to
National Glycohemoglobin Standardization Program
values. J Diabetes Investig, 2012; 3: 39-40
19) Sekikawa A, Mahajan H, Kadowaki S, Hisamatsu T,
Miyagawa N, Fujiyoshi A, Kadota A, Maegawa H, Murata
K, Miura K, Edmundowicz D, Ueshima H; SESSA
Research Group: Association of blood levels of marine
omega-3 fatty acids with coronary calcification and
calcium density in Japanese men. Eur J Clin Nutr, 2019;
73: 783-792
20) Kadota A, Okuda N, Ohkubo T, Okamura T, Nishi N,
Ueshima H, Okayama A, Miura K: The National
Integrated Project for Prospective Observation of Noncommunicable Disease and its Trends in the Aged 2010
(NIPPON DATA2010): Objectives, Design, and
Population Characteristics. J Epidemiol, 2018; 28 Suppl
3: S2-S9
21) Hisamatsu T, Miura K, Fujiyoshi A, Kadota A, Miyagawa
N, Satoh A, Zaid M, Yamamoto T, Horie M, Ueshima H;
SESSA Research Group: Serum magnesium, phosphorus,
and calcium levels and subclinical calcific aortic valve
disease: A population-based study. Atherosclerosis, 2018;
273: 145-152
22) Horio M, Imai E, Yasuda Y, Watanabe T, Matsuo S: GFR
Estimation Using Standardized Serum Cystatin C in
Japan. Am J Kidney Dis, 2013; 61: 197-203
23) Fujiyoshi A, Miura K, Ohkubo T, Miyagawa N, Saito Y,
Miyazawa I, Shiino A, Kadota A, Kadowaki S, Hisamatsu
T, Torii S, Takashima N, Tooyama I, Ueshima H:
Proteinuria and Reduced Estimated Glomerular Filtration
Rate are Independently Associated with Lower Cognitive
Abilities in Apparently Healthy Community-Dwelling
Elderly Men in Japan: A Cross-sectional Study. J
Epidemiol, 2020; 30: 244-252
24) Japanese Society of Nephrology; Essential points from
Evidence-based Clinical Practice Guidelines for Chronic
Kidney Disease 2018. Clin Exp Nephrol, 2018; 23: 1-15
25) Agatston AS, Janowitz WR, Hildner FJ, Zusmer NR,
Viamonte M Jr, Detrano R: Quantification of coronary
artery calcium using ultrafast computed tomography. J
Am Coll Cardiol, 1990; 15: 827-832
26) Sekikawa A, Ueshima H, Kadowaki T, El-Saed A,
Okamura T, Takamiya T, Kashiwagi A, Edmundowicz D,
Murata K, Sutton-Tyrrell K, Maegawa H, Evans RW, Kita
Y, Kuller LH: Less subclinical atherosclerosis in Japanese
men in Japan than in White men in the United States in
the post-World War II birth cohort. Am J Epidemiol,
2007; 165: 617-624
27) Berry JD, Liu K, Folsom AR, Lewis CE, Carr JJ, Polak JF,
Shea S, Sidney S, O’Leary DH, Chan C, Lloyd-Jones
DM: Prevalence and progression of subclinical
atherosclerosis in younger adults with low short-term but
high lifetime estimated risk for cardiovascular disease: the
coronary artery risk development in young adults study
and multi-ethnic study of atherosclerosis. Circulation,
2009; 119: 382-389
28) Zou G: A modified poisson regression approach to
prospective studies with binary data. Am J Epidemiol,
2004; 159: 702-706
29) Kestenbaum BR, Adeney KL, de Boer IH, Ix JH, Shlipak
MG, Siscovick DS: Incidence and progression of coronary
calcification in chronic kidney disease: the Multi-Ethnic
Study of Atherosclerosis. Kidney Int, 2009; 76: 991-998
30) Sedaghat S, Hoorn EJ, Ikram MA, Koop-Nieuwelink C,
Kavousi M, Franco OH, van der Lugt A, Vernooij MW,
Bos D: Kidney Function and Arterial Calcification in
Major Vascular Beds. J Am Heart Assoc, 2019; 8:
e010930
31) Seliger SL, Salimi S, Pierre V, Giffuni J, Katzel L, Parsa A:
Microvascular endothelial dysfunction is associated with
albuminuria and CKD in older adults. BMC Nephrol,
2016; 17: 82
32) Garsen M, Rops AL, Rabelink TJ, Berden JH, van der
Vlag J: The role of heparanase and the endothelial
glycocalyx in the development of proteinuria. Nephrol
Dial Transplant, 2014; 29: 49-55
33) Malyszko J: Mechanism of endothelial dysfunction in
chronic kidney disease. Clin Chim Acta, 2010; 411:
1412-1420
34) Manabe S, Kataoka H, Mochizuki T, Iwadoh K, Ushio Y,
Kawachi K, Watanabe K, Watanabe S, Akihisa T, Makabe
S, Sato M, Iwasa N, Yoshida R, Sawara Y, Hanafusa N,
Tsuchiya K, Nitta K: Maximum Carotid Intima-Media
Thickness in Association with Renal Outcomes. J
Atheroscler Thromb, 2021; 28: 491-505
35) Li Y, Cui R, Liu K, Eshak ES, Cui M, Dong J, Imano H,
Muraki I, Kiyama M, Kitamura A, Okada T, Yamagishi K,
Umesawa M, Ohira T, Iso H; CIRCS investigators:
Relationship between Endothelial Dysfunction and
Prevalence of Chronic Kidney Disease: The Circulatory
Advance Publication Journal of Atherosclerosis and Thrombosis
Accepted for publication: September 12, 2021 Published online: October 22, 2021
Ganbaatar et al .
Risk in Communities Study (CIRCS). J Atheroscler
Thromb, 2021; 28: 622-629
36) Harada A, Ueshima H, Kinoshita Y, Miura K, Ohkubo T,
Asayama K, Ohashi Y; Japan Arteriosclerosis Longitudinal
Study Group: Absolute risk score for stroke, myocardial
infarction, and all cardiovascular disease: Japan
Arteriosclerosis Longitudinal Study. Hypertens Res, 2019;
42: 567-579
37) Song X, Li J, Hua Y, Wang C, Liu B, Liu C, Zhao Q,
Zhang Z, Fang X, Wu J: Chronic Kidney Disease is
Associated with Intracranial Artery Stenosis Distribution
in the Middle-Aged and Elderly Population. J Atheroscler
Thromb, 2020; 27: 245-254
38) Bundy JD, Chen J, Yang W, Budoff M, Go AS, Grunwald
JE, Kallem RR, Post WS, Reilly MP, Ricardo AC, Rosas
SE, Zhang X, He J; CRIC Study Investigators: Risk
factors for progression of coronary artery calcification in
patients with chronic kidney disease: The CRIC study.
Atherosclerosis, 2018; 271: 53-60
39) Hyun YY, Kim H, Oh KH, Ahn C, Park SK, Chae DW,
Oh YK, Choi KH, Han SH, Kim YH, Lee KB: eGFR and
coronary artery calcification in chronic kidney disease.
10
Eur J Clin Invest, 2019; 13: e13101
40) Shlipak MG, Sarnak MJ, Katz R, Fried LF, Seliger SL,
Newman AB, Siscovick DS, Stehman-Breen C: Cystatin
C and the risk of death and cardiovascular events among
elderly persons. N Engl J Med, 2005; 352: 2049-2060
41) Shlipak MG, Matsushita K, Ärnlöv J, Inker LA, Katz R,
Polkinghorne KR, Rothenbacher D, Sarnak MJ, Astor
BC, Coresh J, Levey AS, Gansevoort RT; CKD Prognosis
Consortium: Cystatin C versus Creatinine in
Determining Risk Based on Kidney Function. N Engl J
Med, 2013; 369: 932-943
42) Matsushita K, Coresh J, Sang Y, Chalmers J, Fox C,
Guallar E, Jafar T, Jassal SK, Landman GW, Muntner P,
Roderick P, Sairenchi T, Schöttker B, Shankar A, Shlipak
M, Tonelli M, Townend J, van Zuilen A, Yamagishi K,
Yamashita K, Gansevoort R, Sarnak M, Warnock DG,
Woodward M, Ärnlöv J; CKD Prognosis Consortium:
Estimated glomerular filtration rate and albuminuria for
prediction of cardiovascular outcomes: a collaborative
meta-analysis of individual participant data. Lancet
Diabetes Endocrinol, 2015; 3: 514-525
Advance Publication Journal of Atherosclerosis and Thrombosis
Accepted for publication: September 12, 2021 Published online: October 22, 2021
Kidney Function and CAC Progression
Supplemental Table 1. Odds ratios of the presence of CAC progression by kidney function according to albuminuria or low eGFR
in 760 men aged 40-79 years with a mean follow-up of 4.9 years in the SESSA Study
Albuminuria
Low eGFRcys
Low eGFRcre
Unadjusted OR
(95% CI)
Model 1 OR
(95% CI)
Model 2 OR
(95% CI)
Model 3 OR
(95% CI)
Model 4 OR
(95% CI)
1.74 (1.19 - 2.54)
2.10 (1.39 - 3.18)
1.27 (0.86 - 1.88)
1.69 (1.15 - 2.50)
1.73 (1.11 - 2.69)
1.07 (0.71 - 1.61)
1.70 (1.14 - 2.52)
1.60 (1.02 - 2.51)
1.03 (0.68 - 1.55)
1.32 (0.86 - 2.02)
1.55 (0.97 - 2.47)
0.97 (0.63 - 1.49)
1.52 (1.01 - 2.30)
1.56 (0.98 - 2.47)
0.99(0.65 - 1.52)
OR, odds ratio; 95% CI, 95% confidence interval;
Albuminuria described as ＞ 30mg/g; Low eGFR by cystatin C described as ＜ 60 ml/min/1.73m2; Low eGFR by creatinine described as ＜ 60 ml/
min/1.73m2; A multivariable logistic regression analysis was used to estimate odds ratio with 95% CI; Model 1 was adjusted for age, follow up
period, CT type; Model 2 further adjusted by BMI, step counts, current-smoker, current-drinker; Model 3 was further adjusted for SBP, HDL-C,
LDL-C, logTG, HbA1C, hypertension medication, diabetes medication, lipid medication, log-CRP; Model 4 was adjusted for Model 2 plus
hypertension, diabetes, dyslipidemia, log-CRP.
Supplemental Table 2. Multivariable adjusted odds ratios of CAC progression by kidney function according to mutually adjusted
albuminuria with low eGFRcys and that with low eGFRcre in 760 men aged 40-79 years with a mean
follow-up of 4.9 years in the SESSA Study
a) Albuminuria and low eGFRcys
Model 1
Model 2
Model 3
Model 4
b) Albuminuria and low eGFRcre
Model 1
Model 2
Model 3
Model 4
Albuminuria OR (95% CI)
Low eGFRcys OR (95% CI)
Low eGFRcre OR (95% CI)
1.62 (1.09 - 2.40)
1.64 (1.10 - 2.45)
1.29 (0.84 - 1.98)
1.48 (0.98 - 2.25)
1.63 (1.05 - 2.55)
1.52 (0.97 - 2.40)
1.52 (0.96 - 2.43)
1.52 (0.96 - 2.40)
1.69 (1.14 - 2.50)
1.70 (1.14 - 2.52)
1.32 (0.86 - 2.03)
1.52 (1.01 - 2.31)
1.02 (0.68 - 1.55)
0.99 (0.65 - 1.50)
0.96 (0.62 - 1.48)
0.97 (0.64 - 1.49)
OR, odds ratio; 95% CI, 95% confidence interval;
a) Both albuminuria and low eGFRcys included in the model; b) Both albuminuria and low eGFRcre included in the model; Albuminuria
described as ＞ 30mg/g; Low eGFR by cystatin C described as ＜ 60 ml/min/1.73m2. Low eGFR by creatinine described as ＜ 60 ml/min/1.73m2. A
multivariable logistic regression analysis was used to estimate the odds ratio with 95% CI; Model 1 was adjusted for age, follow up period, CT type;
Model 2 further adjusted by BMI, step counts, current-smoker, current-drinker; Model 3 was further adjusted for SBP, HDL-C, LDL-C, logTG,
HbA1C, hypertension medication, diabetes medication, lipid medication, log-CRP; Model 4 was adjusted for Model 2 plus hypertension, diabetes,
dyslipidemia, log-CRP.
Supplemental Table 3. Relative risk of CAC progression in 479 men, excluding those with CAC = 0 at baseline, according to
albuminuria or low eGFR (age 40-79 years with a mean follow-up of 4.9 years) in the SESSA Study
Albuminuria
Low eGFRcys
Low eGFRcre
Unadjusted RR
(95% CI)
Model 1 RR
(95% CI)
Model 2 RR
(95% CI)
Model 3 RR
(95% CI)
Model 4 RR
(95% CI)
1.12 (0.94 - 1.34)
1.32 (1.10 - 1.57)
1.06 (0.86 - 1.30)
1.12 (0.94 - 1.33)
1.21 (1.01 - 1.46)
1.01 (0.83 - 1.23)
1.14 (0.96 - 1.36)
1.19 (0.99 - 1.44)
1.02 (0.84 - 1.23)
1.07 (0.89 - 1.28)
1.17 (0.97 - 1.41)
1.01 (0.83 - 1.23)
1.12 (0.94 - 1.34)
1.19 (0.98 - 1.43)
1.00 (0.82 - 1.21)
RR, relative risk; 95% CI, 95% confidence interval; Albuminuria described as ＞ 30mg/g. Low eGFR by cystatin C described as ＜ 60 ml/
min/1.73m2. Low eGFR by creatinine described as ＜ 60 ml/min/1.73m2. A robust Poisson regression model was used to estimate RR and 95% CI;
Model 1 adjusted for age, CT type; Model 2 further adjusted for BMI, step counts, current-smoker, current-drinker; Model 3 further adjusted for
SBP, HDL-C, LDL-C, log TG, HbA1C, hypertension medication, diabetes medication, lipid medication, log-CRP; Model 4 adjusted for Model 2
plus hypertension, diabetes, dyslipidemia, log-CRP.
Advance Publication Journal of Atherosclerosis and Thrombosis
Accepted for publication: September 12, 2021 Published online: October 22, 2021
11
Ganbaatar et al .
Supplemental Table 4. Relative risk of CAC progression in 479 men, excluding those with CAC = 0 at baseline, according to
mutually adjusted low eGFRcys with albuminuria and low eGFRcre with albuminuria (age 40-79 years
with a mean follow-up of 4.9 years) in the SESSA Study
a) Albuminuria and low eGFRcys
Model 1
Model 2
Model 3
Model 4
b) Albuminuria and low eGFRcre
Model 1
Model 2
Model 3
Model 4
Albuminuria RR (95% CI)
Low eGFRcys RR (95% CI)
Low eGFRcre RR (95% CI)
1.10 (0.92 - 1.31)
1.12 (0.94 - 1.34)
1.05 (0.88 - 1.27)
1.11 (0.92 - 1.32)
1.20 (0.99 - 1.44)
1.17 (0.97 - 1.42)
1.16 (0.96 - 1.40)
1.18 (0.97 - 1.42)
1.12 (0.94 - 1.34)
1.14 (0.96 - 1.36)
1.07 (0.89 - 1.29)
1.13 (0.94 - 1.35)
1.00 (0.82 - 1.22)
1.00 (0.82 - 1.22)
1.00 (0.82 - 1.22)
0.99 (0.81 - 1.20)
RR, relative risk; 95% CI, 95% confidence interval; a) Both albuminuria and low eGFRcys included in the model; b) Both albuminuria and low
eGFRcre included in the model; Albuminuria described as ＞ 30mg/g; Low eGFR by cystatin C described as ＜ 60 ml/min/1.73m2. Low eGFR by
creatinine described as ＜ 60 ml/min/1.73m2. A robust Poisson regression model was used to estimate RR and 95% CI; Model 1 adjusted for age,
CT type; Model 2 further adjusted for BMI, step counts, current-smoker, current-drinker; Model 3 further adjusted for SBP, HDL-C, LDL-C, log
TG, HbA1C, hypertension medication, diabetes medication, lipid medication, log-CRP; Model 4 adjusted for Model 2 plus hypertension, diabetes,
dyslipidemia, log-CRP.
Supplemental Table 5. Relative risk of CAC progression in 595 men, excluding those with CAC ＞ 100 at baseline, according to
albuminuria or low eGFR (age 40-79 years with a mean follow-up of 4.9 years) in the SESSA Study
Albuminuria
Low eGFRcys
Low eGFRcre
Unadjusted RR
(95% CI)
Model 1 RR
(95% CI)
Model 2 RR
(95% CI)
Model 3 RR
(95% CI)
Model 4 RR
(95% CI)
1.39 (1.09 - 1.76)
1.32 (1.01 - 1.73)
1.11 (0.84 - 1.47)
1.38 (1.09 - 1.75)
1.19 (0.90 - 1.58)
1.04 (0.78 - 1.37)
1.38 (1.09 - 1.75)
1.18 (0.89 - 1.56)
1.04 (0.78 - 1.38)
1.19 (0.93 - 1.52)
1.10 (0.84 - 1.45)
0.95 (0.72 - 1.26)
1.29 (1.02 - 1.64)
1.13 (0.86 - 1.49)
1.01 (0.77 - 1.34)
RR, relative risk; 95% CI, 95% confidence interval; Albuminuria described as ＞ 30mg/g. Low eGFR by cystatin C described as ＜ 60 ml/
min/1.73m2. Low eGFR by creatinine described as ＜ 60 ml/min/1.73m2. A robust Poisson regression model was used to estimate RR and 95% CI;
Model 1 adjusted for age, follow up period, CT type; Model 2 further adjusted for BMI, step counts, current-smoker, current-drinker; Model 3
further adjusted for SBP, HDL-C, LDL-C, log TG, HbA1C, hypertension medication, diabetes medication, lipid medication, log-CRP; Model 4
adjusted for Model 2 plus hypertension, diabetes, dyslipidemia, log-CRP.
12
Advance Publication Journal of Atherosclerosis and Thrombosis
Accepted for publication: September 12, 2021 Published online: October 22, 2021
Kidney Function and CAC Progression
Supplemental Table 6. Relative risk of CAC progression in 595 men, excluding those with CAC ＞ 100 at baseline, with mutually
adjusted low eGFRcys and albuminuria and low eGFRcre and albuminuria (age 40-79 years with a mean
follow-up of 4.9 years) in the SESSA Study
a) Albuminuria and low eGFRcys
Model 1
Model 2
Model 3
Model 4
b) Albuminuria and low eGFRcre
Model 1
Model 2
Model 3
Model 4
Albuminuria RR
(95% CI)
Low eGFRcys RR
(95% CI)
Low eGFRcre RR
(95% CI)
1.37 (1.08 - 1.74)
1.37 (1.08 - 1.74)
1.19 (0.93 - 1.52)
1.29 (1.01 - 1.64)
1.17 (0.88 - 1.55)
1.16 (0.87 - 1.53)
1.09 (0.83 - 1.44)
1.12 (0.85 - 1.48)
1.38 (1.09 - 1.75)
1.38 (1.09 - 1.75)
1.19 (0.93 - 1.52)
1.29 (1.02 - 1.64)
1.02 (0.77 - 1.35)
1.02 (0.77 - 1.35)
0.95 (0.72 - 1.26)
1.01 (0.76 - 1.33)
RR, relative risk; 95% CI, 95% confidence interval; a) Both albuminuria and low eGFRcys included in the model; b) Both albuminuria and low
eGFRcre included in the model; Albuminuria described as ＞ 30mg/g; Low eGFR by cystatin C described as ＜ 60 ml/min/1.73m2. Low eGFR by
creatinine described as ＜ 60 ml/min/1.73m2. A robust Poisson regression model was used to estimate RR and 95% CI; Model 1 adjusted for age,
follow up period, CT type; Model 2 further adjusted for BMI, step counts, current-smoker, current-drinker; Model 3 further adjusted for SBP,
HDL-C, LDL-C, log TG, HbA1C, hypertension medication, diabetes medication, lipid medication, log-CRP; Model 4 adjusted for Model 2 plus
hypertension, diabetes, dyslipidemia, log-CRP.
Advance Publication Journal of Atherosclerosis and Thrombosis
Accepted for publication: September 12, 2021 Published online: October 22, 2021
13
...
論文の公開元へ
